Inverness Medical Innovations introduced the pima analyzer with a unique test platform that allows immunological testing at Point-of-Care. The initial application of the instrument will be CD4 cell enumeration test. Clinical trials began in the 4th quarter 2008 and the instrument with CD4 application will be launched to select markets in mid 2009. Inverness has featured the product at the 15th Annual Conference on AIDS and STIs (ICASA) in Dakar, Senegal. In individuals who have been confirmed as being HIV positive, CD4 testing is an important baseline measurement to gauge the state of their immune system and for clinicians to initiate antiretroviral (ART) HIV therapy. Measurement of CD4 levels indicates as how far the disease has advanced and the risk to the patient of debilitating infections or complications. Apart from the baseline measurement, CD4 is also measured generally 2 to 4 times annually during course of HIV therapy. The Inverness system design is optimal for use in point of care settings in the developing world as well as in the doctor's office in the developed world. It is a simple to operate, portable system with a rechargeable battery and provides rapid results. Using a small finger stick blood sample, the platform would be able to deliver not just CD4 cell enumeration but ultimately allow analysis of a wide array of additional markers.